Roots Analysis
FEBRUARY 15, 2023
Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. As per our analysis, North America and Europe, with the highest number of technology as well as service providers, have emerged as key hubs.
Camargo
FEBRUARY 10, 2021
Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
DECEMBER 22, 2021
One of Camargo’s differentiating offerings is the portfolio analysis, a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio. Each product is unique, and so is the associated development strategy. Why Conduct a Portfolio Analysis?
Camargo
SEPTEMBER 30, 2021
Nonclinical programs include (but are not limited to) method development and validation, pharmacokinetic studies, in vivo efficacy studies, safety pharmacology, IND-enabling toxicology studies, and long-term studies when appropriate. Overview of Drug Development Programs (Through IND Submission). CMC Considerations. Non-scalable process.
The Pharma Data
DECEMBER 9, 2020
Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. .
Pharmaceutical Technology
MAY 31, 2023
CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). C4T can also earn up to $357m in milestone payments and receive low to mid-double-digit percentage royalties on net sales of the product in greater China.
Pharmaceutical Technology
FEBRUARY 13, 2023
Best practice is to also consider the ‘developability’ of the lead compounds in conjunction with any evidence of potential in-vivo activity, by taking a holistic approach. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?
Expert insights. Personalized for you.
52 
Let's personalize your content